282 related articles for article (PubMed ID: 25373787)
1. Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer.
Mego M; Zuo Z; Gao H; Cohen EN; Giordano A; Tin S; Anfossi S; Jackson S; Woodward W; Ueno NT; Valero V; Alvarez RH; Hortobagyi GN; Khoury JD; Cristofanilli M; Reuben JM
Thromb Haemost; 2015 Mar; 113(3):593-8. PubMed ID: 25373787
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients.
Mego M; De Giorgi U; Broglio K; Dawood S; Valero V; Andreopoulou E; Handy B; Reuben JM; Cristofanilli M
Br J Cancer; 2009 Dec; 101(11):1813-6. PubMed ID: 19888227
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumour cells and hypercoagulability: a lethal relationship in metastatic breast cancer.
Kirwan CC; Descamps T; Castle J
Clin Transl Oncol; 2020 Jun; 22(6):870-877. PubMed ID: 31473984
[TBL] [Abstract][Full Text] [Related]
4. Relationship between circulating tumor cells, blood coagulation, and urokinase-plasminogen-activator system in early breast cancer patients.
Mego M; Karaba M; Minarik G; Benca J; Sedlácková T; Tothova L; Vlkova B; Cierna Z; Janega P; Luha J; Gronesova P; Pindak D; Fridrichova I; Celec P; Reuben JM; Cristofanilli M; Mardiak J
Breast J; 2015; 21(2):155-60. PubMed ID: 25623304
[TBL] [Abstract][Full Text] [Related]
5. Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients.
Banys-Paluchowski M; Witzel I; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer EF; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Müller V
Anticancer Res; 2017 Jun; 37(6):3117-3128. PubMed ID: 28551653
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor cell count and thrombosis in metastatic breast cancer.
Beinse G; Berger F; Cottu P; Dujaric ME; Kriegel I; Guilhaume MN; Diéras V; Cabel L; Pierga JY; Bidard FC
J Thromb Haemost; 2017 Oct; 15(10):1981-1988. PubMed ID: 28779538
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
[TBL] [Abstract][Full Text] [Related]
10. Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes.
Peeters DJ; van Dam PJ; Van den Eynden GG; Rutten A; Wuyts H; Pouillon L; Peeters M; Pauwels P; Van Laere SJ; van Dam PA; Vermeulen PB; Dirix LY
Br J Cancer; 2014 Jan; 110(2):375-83. PubMed ID: 24366294
[TBL] [Abstract][Full Text] [Related]
11. Preoperative plasma D-dimer predicts 1-year survival in colorectal cancer patients with absence of venous thromboembolism (VTE): a prospective clinical cohort study.
Stender MT; Larsen TB; Sørensen HT; Thorlacius-Ussing O
J Thromb Haemost; 2012 Oct; 10(10):2027-31. PubMed ID: 22900573
[TBL] [Abstract][Full Text] [Related]
12. Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer.
Botteri E; Sandri MT; Bagnardi V; Munzone E; Zorzino L; Rotmensz N; Casadio C; Cassatella MC; Esposito A; Curigliano G; Salvatici M; Verri E; Adamoli L; Goldhirsch A; Nolè F
Breast Cancer Res Treat; 2010 Jul; 122(1):211-7. PubMed ID: 19967556
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumour cells and lung microvascular tumour cell retention in patients with metastatic breast and cervical cancer.
Peeters DJ; Brouwer A; Van den Eynden GG; Rutten A; Onstenk W; Sieuwerts AM; Van Laere SJ; Huget P; Pauwels P; Peeters M; Vermeulen PB; Dirix LY
Cancer Lett; 2015 Jan; 356(2 Pt B):872-9. PubMed ID: 25449778
[TBL] [Abstract][Full Text] [Related]
14. [Estimation of venous thromboembolism risk with thrombotic biomarkers in cancer patients].
Jianlong M; Diansheng Z; Jing R
Zhonghua Zhong Liu Za Zhi; 2015 Apr; 37(4):283-9. PubMed ID: 26462893
[TBL] [Abstract][Full Text] [Related]
15. Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients.
Giordano A; Giuliano M; De Laurentiis M; Eleuteri A; Iorio F; Tagliaferri R; Hortobagyi GN; Pusztai L; De Placido S; Hess K; Cristofanilli M; Reuben JM
Breast Cancer Res Treat; 2011 Sep; 129(2):451-8. PubMed ID: 21710134
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?
Dawood S; Broglio K; Valero V; Reuben J; Handy B; Islam R; Jackson S; Hortobagyi GN; Fritsche H; Cristofanilli M
Cancer; 2008 Nov; 113(9):2422-30. PubMed ID: 18785255
[TBL] [Abstract][Full Text] [Related]
17. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study.
Ay C; Vormittag R; Dunkler D; Simanek R; Chiriac AL; Drach J; Quehenberger P; Wagner O; Zielinski C; Pabinger I
J Clin Oncol; 2009 Sep; 27(25):4124-9. PubMed ID: 19636003
[TBL] [Abstract][Full Text] [Related]
18. Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.
Huebner H; Fasching PA; Gumbrecht W; Jud S; Rauh C; Matzas M; Paulicka P; Friedrich K; Lux MP; Volz B; Gass P; Häberle L; Meier-Stiegen F; Hartkopf A; Neubauer H; Almstedt K; Beckmann MW; Fehm TN; Ruebner M
BMC Cancer; 2018 Feb; 18(1):204. PubMed ID: 29463222
[TBL] [Abstract][Full Text] [Related]
19. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
20. Detection and prognostic relevance of circulating tumour cells (CTCs) in Asian breast cancers using a label-free microfluidic platform.
Yap YS; Leong MC; Chua YW; Loh KWJ; Lee GE; Lim EH; Dent R; Ng RCH; Lim JH; Singh G; Tan A; Guan G; Wu A; Lee YF; Bhagat AAS; Lim DW
PLoS One; 2019; 14(9):e0221305. PubMed ID: 31553731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
